Population Pharmacokinetics of Lamivudine in Adult Human Immunodeficiency Virus-Infected Patients Enrolled in Two Phase III Clinical Trials

Lamivudine population pharmacokinetics were investigated by using nonlinear mixed-effect modelling (NONMEM) analysis of data from 394 human immunodeficiency virus (HIV)-infected patients treated with lamivudine (150 to 300 mg every 12 h) in two large, phase III clinical efficacy-safety trials, NUCA3...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Moore, Katy H. P., Yuen, Geoffrey J., Hussey, Elizabeth K., Pakes, Gary E., Eron, Joseph J., Bartlett, John A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society for Microbiology 1999
Konular:
Antiviral Agents
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC89609/
https://ncbi.nlm.nih.gov/pubmed/10582904
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller